Effects of Arylsulfatase B and Pembrolizumab in Combination on Melanoma

Joanne Tobacman published data underlying a 2026 Frontiers in Oncology manuscript. The dataset supports findings on how recombinant human Arylsulfatase B interacts with Pembrolizumab to improve therapeutic responses in melanoma. It likely contains experimental results on apoptosis, metalloproteinase levels, and cytokine expression from syngeneic B16F10 mouse models.

Use Cases

• Analyzing synergistic effects on tumor progression based on combined ARSB and Pembrolizumab treatment mentioned in the description
• Investigating changes in apoptosis rates based on Constitutive Photomorphogenic (COP)1 expression
• Modeling declines in metalloproteinases and invasiveness following therapeutic intervention
• Studying alterations in cytokine expression profiles resulting from the combination therapy

Strengths

• Data directly supports a peer-reviewed manuscript to be published in Frontiers in Oncology
• Focuses on a specific, novel combination therapy (ARSB and Pembrolizumab) for melanoma
• File size is 393.0 KB, indicating a focused and likely manageable dataset

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• Data is from a single, specific preclinical mouse model (B16F10), which may limit generalizability

Provenance

Source

figshare

Collection Method

Experimental data from syngeneic B16F10 mouse melanoma studies.

Freshness

Last updated 2026-05-27 18:17:38